title: Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
abstract: Therion Biologics Corp is developing PROSTVAC-VF-TRICOM, a prime-boost vaccine regimen that consists of a priming injection with a recombinant attenuated vaccinia virus expressing PSA and TRICOM (the company's proprietary triad of costimulatory molecules: ICAM-1, B7.1 and lymphocyte function-associated antigen-3), and a booster injection with a fowlpox virus expressing the same combination, for the potential treatment of prostate cancer. Phase II clinical trials are underway.
authors: University of Lübeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
authors: Christian
authors: C
authors: Doehn
authors: Ingo
authors: I
authors: Kausch
authors: Torsten
authors: T
authors: Böhmer
authors: Martin
authors: M
authors: Sommerauer
authors: Dieter
authors: D
authors: Jocham
mesh_terms: D019496:Cancer Vaccines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D010330:Patents as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship
chemical_list: D019496:Cancer Vaccines